Highest-materiality recent filing
Artiva CFO departs; CEO assumes financial duties; Miralles becomes President
CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering
Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.
Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027
Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA
Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial
Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.
Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025
Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.
Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026
IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.
On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026
On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.
On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026
On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders
appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board
Max materiality 0.85 · Median 0.57 · Most common event earnings